01—History
Long-Term Debt History
Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025. Drag across the bars to change the range.
- $8.57B
02—Ledger
03—Questions
What is long-term debt?
Long-term debt includes bonds, mortgages, and other borrowings with maturities greater than one year.
What is Royalty Pharma's current long-term debt?
Royalty Pharma (RPRX) annual long-term debt for 2025 was $8.57B, a 29.57% increase from 2024. Royalty Pharma long-term debt for the quarter ending June 30, 2026 was $8.58B.
What was Royalty Pharma's long-term debt in 2024?
Royalty Pharma annual long-term debt for 2024 was $6.61B, a 7.81% increase from 2023.
What was Royalty Pharma's long-term debt in 2023?
Royalty Pharma annual long-term debt for 2023 was $6.14B, a 0.27% increase from 2022.
What is Royalty Pharma's 5-year long-term debt CAGR?
Royalty Pharma long-term debt grew at a compound annual growth rate (CAGR) of 8.06% from FY2020 to FY2025, going from $5.82B to $8.57B over 5 years.
- Company
- Royalty Pharma
- Ticker
- RPRX
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations